Cover Image
市場調查報告書

肺腺癌:開發中產品分析

Lung Adenocarcinoma - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 251516
出版日期 內容資訊 英文 132 Pages
訂單完成後即時交付
價格
Back to Top
肺腺癌:開發中產品分析 Lung Adenocarcinoma - Pipeline Review, H2 2015
出版日期: 2015年12月16日 內容資訊: 英文 132 Pages
簡介

肺腺癌大致是由外側部分的細胞開始發生,在症狀產生或受到診斷前有可能早就存在了。其症狀有慢性咳嗽、此外除非到疾病後期否則一般不會有咳血的症狀。腺癌初期可判斷的症狀有疲勞感、輕度呼吸困難、以及背後、肩膀、或是胸口感到疼痛。治療方法有化療及放射線療法。

本報告提供全球治療肺腺癌用的開發中產品之開發情形相關分析,提供產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

肺腺癌概要

治療藥的開發

  • 肺腺癌開發中產品:概要
  • 肺腺癌開發中產品:比較分析

肺腺癌:各企業開發中的治療藥

肺腺癌:大學/研究機關研究中的治療藥

肺腺癌:開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

肺腺癌:開發中的產品一覽(各企業)

肺腺癌:研究中的產品一覽(大學/研究機關別)

肺腺癌的開發企業

  • Boehringer Ingelheim GmbH
  • Amgen Inc.
  • Merck & Co., Inc.
  • 武田藥品工業
  • Pfizer Inc.
  • Genmab A/S.
  • Immunomedics, Inc.
  • Quantum Pharmaceuticals
  • BioNumerik Pharmaceuticals, Inc.
  • Axelar AB.
  • VG Life Sciences, Inc.
  • Medisyn Technologies, Inc.
  • Vichem Chemie Research Ltd.
  • Hanmi Pharmaceuticals, Co. Ltd.

肺腺癌:治療藥的評估

  • 單獨療法的情況
  • 是聯合治療的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • dimesuna
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • afatinib
  • dacomitinib
  • AXL-1717
  • vintafolide
  • Cell Therapy to Inhibit CD40L for Metastatic Lung Cancer and Lung Adenocarcinoma
  • poziotinib
  • metformin + [bevacizumab] + [carboplatin] + [paclitaxel]
  • Stem Cell Therapy for Metastatic Adenocarcinomas
  • solitomab
  • SNX-5422
  • hydroxychloroquine + sorafenib tosylate
  • MT-477
  • Tylophorine Analogs
  • Drug to inhibit GATA2 transcriptional targets for Lung Cancer
  • Small Molecules To Inhibit Phosphofructokinase-2 For Neurodegenerative Diseases And Cancer
  • Interferon Lambda-1 Linked Fab Dimer
  • TEMPO-IND
  • Lysosomal Acid Ceramidase Inhibitors for Prostate Cancer and Lung Adenocarcinoma
  • TF-011-Monomethyl Auristatin E
  • Small Molecule Antagonist to PDGFR And VEGFR-2 for Oncology
  • DBPR-112
  • TEMPO-ASA
  • Small Molecule to Inhibit EGFR for Oncology

肺腺癌:開發中產品的最新趨勢

肺腺癌:開發暫停的產品

肺腺癌相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7456IDB

Summary

Global Markets Direct's, 'Lung Adenocarcinoma - Pipeline Review, H2 2015', provides an overview of the Lung Adenocarcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lung Adenocarcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Lung Adenocarcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Lung Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Lung Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lung Adenocarcinoma Overview
  • Therapeutics Development
    • Pipeline Products for Lung Adenocarcinoma - Overview
    • Pipeline Products for Lung Adenocarcinoma - Comparative Analysis
  • Lung Adenocarcinoma - Therapeutics under Development by Companies
  • Lung Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes
  • Lung Adenocarcinoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Lung Adenocarcinoma - Products under Development by Companies
  • Lung Adenocarcinoma - Products under Investigation by Universities/Institutes
  • Lung Adenocarcinoma - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Astex Pharmaceuticals, Inc.
    • AstraZeneca Plc
    • AVEO Pharmaceuticals, Inc.
    • Axelar AB
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Eisai Co., Ltd.
    • Genentech, Inc.
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Immunomedics, Inc.
    • Incyte Corporation
    • Johnson & Johnson
    • Morphotek, Inc.
    • Pfizer Inc.
    • Sanofi
    • VG Life Sciences, Inc.
    • Vichem Chemie Research Ltd.
  • Lung Adenocarcinoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • afatinib dimaleate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AV-203 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AXL-1717 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AZD-6738 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAY-1163877 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dacomitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DBPR-112 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EB-102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • farletuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hydroxychloroquine + sorafenib tosylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JNJ-42756493 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lenvatinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAG-Tn3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • poziotinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Agonize Interferon Lamda Receptor 1 for Oncology and Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ruxolitinib phosphate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAR-408701 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit EGFR for Non-Small Cell Lung Cancer and Lung Adenocarcinoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SNX-5422 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • solitomab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TdCyd - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VAL-401 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lung Adenocarcinoma - Recent Pipeline Updates
  • Lung Adenocarcinoma - Dormant Projects
  • Lung Adenocarcinoma - Product Development Milestones
    • Featured News & Press Releases
      • May 29, 2015: Spectrum Pharmaceuticals Highlights Abstract of Clinical Data For Poziotinib at the 2015 ASCO Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Lung Adenocarcinoma, H2 2015
  • Number of Products under Development for Lung Adenocarcinoma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Lung Adenocarcinoma - Pipeline by Amgen Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by AstraZeneca Plc, H2 2015
  • Lung Adenocarcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by Axelar AB, H2 2015
  • Lung Adenocarcinoma - Pipeline by Bayer AG, H2 2015
  • Lung Adenocarcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Lung Adenocarcinoma - Pipeline by Eisai Co., Ltd., H2 2015
  • Lung Adenocarcinoma - Pipeline by Genentech, Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
  • Lung Adenocarcinoma - Pipeline by Immunomedics, Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by Incyte Corporation, H2 2015
  • Lung Adenocarcinoma - Pipeline by Johnson & Johnson, H2 2015
  • Lung Adenocarcinoma - Pipeline by Morphotek, Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by Pfizer Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by Sanofi, H2 2015
  • Lung Adenocarcinoma - Pipeline by VG Life Sciences, Inc., H2 2015
  • Lung Adenocarcinoma - Pipeline by Vichem Chemie Research Ltd., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Lung Adenocarcinoma Therapeutics - Recent Pipeline Updates, H2 2015
  • Lung Adenocarcinoma - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Lung Adenocarcinoma, H2 2015
  • Number of Products under Development for Lung Adenocarcinoma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top